iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Up 112.4% in February

iBio, Inc. (NYSEAMERICAN:IBIO) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 454,200 shares, a growth of 112.4% from the January 31st total of 213,800 shares. Approximately 4.9% of the shares of the company are sold short. Based on an average trading volume of 239,400 shares, the short-interest ratio is presently 1.9 days.

iBio Stock Performance

Shares of IBIO traded up $0.78 during trading hours on Friday, hitting $5.83. The stock had a trading volume of 1,352,886 shares, compared to its average volume of 492,873. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04. iBio has a 12 month low of $1.05 and a 12 month high of $5.83.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.